Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

1. Population - Group 1. Healthy co-habitants (n = 30) Inclusion criteria: * Household co-habitant of transplant recipient in trial * Aged \>50 years * Previous documented infection with VZV (known infection history or positive VZV IgG result) Exclusion criteria: * Aged \<50 years * Unable or unwilling to provide informed consent to participate in the trial * Known allergy to or intolerance of the contents of the RZV vaccine * No previous infection with VZV (chickenpox) * History of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy 2. Population - Groups 2-4. Transplant recipients (n = 90) Inclusion criteria: * Organ transplant recipients \-- Specific immunosuppression regimen * Tacrolimus, mycophenolate, prednisolone (n = 30, Group 2) * Tacrolimus, mTORi, prednisolone (n = 30, Group 3) * mTORi, mycophenolate, prednisolone (n = 30, Group 4) * Aged \>18 years * estimated GFR \> 15 mL/min/1.73m2 * Previous documented infection with VZV (known infection history or positive VZV IgG result) Exclusion criteria: * Aged \<18 years * Unable or unwilling to provide informed consent to participate in the trial * No previous infection with VZV (chickenpox) * Known allergy to or intolerance of the contents of the RZV vaccine * Current pregnancy 3. Population - Group 5. Other (n = 10) Inclusion criteria: * Immunosuppressed patient receiving single-agent rapamycin immunosuppression * Aged \>18 years * Previous documented infection with VZV (known infection history or positive VZV IgG result) Exclusion criteria: * Aged \<18 years * Unable or unwilling to provide informed consent to participate in the trial * Known allergy to or intolerance of the contents of the RZV vaccine * No previous infection with VZV (chickenpox) * Known allergy to or intolerance of the contents of the RZV vaccine * Current pregnancy * History of primary immunodeficiency, documented vaccine hypo-responsiveness, or active immunosuppressive therapy 4. Population - Group 6. Dialysis group (n = 30) Inclusion criteria: * Kidney failure receiving haemodialysis as kidney replacement therapy * Aged \>18 years * Previous documented infection with VZV (known infection history or positive VZV IgG result) Exclusion criteria: * Aged \<18 years * Unable or unwilling to provide informed consent to participate in the trial * Known allergy to or intolerance of the contents of the RZV vaccine * No previous infection with VZV (chickenpox) * Known allergy to or intolerance of the contents of the RZV vaccine * Current pregnancy * History of primary immunodeficiency or active immunosuppressive therapy